These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 32194573)

  • 41. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
    Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
    Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics.
    Chang KM; Liu M
    Curr Opin Pharmacol; 2016 Oct; 30():93-105. PubMed ID: 27570126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterogeneity of HBV-Specific CD8
    Heim K; Neumann-Haefelin C; Thimme R; Hofmann M
    Front Immunol; 2019; 10():2240. PubMed ID: 31620140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors.
    Lobaina Y; Hardtke S; Wedemeyer H; Aguilar JC; Schlaphoff V
    Mol Immunol; 2015 Feb; 63(2):320-7. PubMed ID: 25193323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming.
    Fisicaro P; Boni C; Barili V; Laccabue D; Ferrari C
    Curr Opin Virol; 2018 Jun; 30():1-8. PubMed ID: 29414066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?
    Hakim MS; Spaan M; Janssen HL; Boonstra A
    Rev Med Virol; 2014 Mar; 24(2):125-38. PubMed ID: 24757728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection.
    Shimizu Y
    World J Gastroenterol; 2012 May; 18(20):2443-51. PubMed ID: 22654441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.
    Chen J; Yuan Z
    Virol Sin; 2014 Feb; 29(1):17-24. PubMed ID: 24452540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.
    Zhu W; Liu H; Zhang X
    ACS Infect Dis; 2019 May; 5(5):703-712. PubMed ID: 30907080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of hepatitis B virus-induced systemic immune tolerance by intrinsic innate immune stimulation.
    Han Q; Lan P; Zhang J; Zhang C; Tian Z
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():132-7. PubMed ID: 23855309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice.
    Yoon SK; Seo YB; Im SJ; Bae SH; Song MJ; You CR; Jang JW; Yang SH; Suh YS; Song JS; Kim BM; Kim CY; Jeong SH; Sung YC
    Liver Int; 2015 Mar; 35(3):805-15. PubMed ID: 24620920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic vaccines in HBV: lessons from HCV.
    Barnes E
    Med Microbiol Immunol; 2015 Feb; 204(1):79-86. PubMed ID: 25573348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.
    Böcher WO; Dekel B; Schwerin W; Geissler M; Hoffmann S; Rohwer A; Arditti F; Cooper A; Bernhard H; Berrebi A; Rose-John S; Shaul Y; Galle PR; Löhr HF; Reisner Y
    Eur J Immunol; 2001 Jul; 31(7):2071-9. PubMed ID: 11449360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
    Zhang TY; Yuan Q; Zhao JH; Zhang YL; Yuan LZ; Lan Y; Lo YC; Sun CP; Wu CR; Zhang JF; Zhang Y; Cao JL; Guo XR; Liu X; Mo XB; Luo WX; Cheng T; Chen YX; Tao MH; Shih JW; Zhao QJ; Zhang J; Chen PJ; Yuan YA; Xia NS
    Gut; 2016 Apr; 65(4):658-71. PubMed ID: 26423112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.
    Hoogeveen RC; Robidoux MP; Schwarz T; Heydmann L; Cheney JA; Kvistad D; Aneja J; Melgaço JG; Fernandes CA; Chung RT; Boonstra A; Kim AY; Baumert TF; Timm J; Lewis-Ximenez LL; Tonnerre P; Lauer GM
    Gut; 2019 May; 68(5):893-904. PubMed ID: 30580250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.
    Inchauspé G; Michel ML
    J Viral Hepat; 2007 Nov; 14 Suppl 1():97-103. PubMed ID: 17958650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection.
    Akbar SM; Horiike N; Onji M
    World J Gastroenterol; 2006 May; 12(18):2876-83. PubMed ID: 16718812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.